- Trial Phase
- Phase 1/2 (discontinued)
- Time to Market
- Unknown — program discontinued internally; potential value only through strategic alternatives (licensing/partnering)
- Why 2/10
- Rejuva has been discontinued internally as of October 22, 2026, with no scheduled catalysts. The company is seeking strategic alternatives, but there is no dated binary event. ImpactScore is 2 — a discontinued program with no upcoming catalysts and uncertain value from potential out-licensing.
Rejuva has been discontinued internally — there are no upcoming catalysts for this drug. Fractyl Health (GUTS) is now a single-asset company betting entirely on its Revita device. Watch for the FDA De Novo submission for Revita (late Q4 2026) and 12-month REMAIN-1 data (Q1 2027), but these are Revita catalysts, not Rejuva. The Rejuva program may generate some value if a strategic partner/license is found, but that is uncertain.
Price Chart
Executive Summary
Rejuva is Fractyl Health's (GUTS) gene therapy program, anchored by RJVA-001, an AAV-based gene therapy candidate for type 2 diabetes. The program had just entered Phase 1/2 clinical testing in the Netherlands in May 2026, but on October 22, 2026, Fractyl announced it was discontinuing internal development of Rejuva as part of a broader restructuring to focus entirely on its Revita device. The company is cutting ~45% of its workforce and seeking strategic alternatives for Rejuva. For investors, Rejuva is effectively a dead program — the stock is now a single-asset bet on Revita, with no further catalysts tied to Rejuva.
How It Works
Rejuva is a gene therapy program using an adeno-associated virus (AAV) vector to deliver a therapeutic gene. In plain terms, it uses a harmless virus as a delivery truck to carry genetic instructions into a patient's cells — in this case, designed to treat type 2 diabetes by potentially restoring the body's ability to regulate blood sugar. The specific candidate, RJVA-001, was in early-stage (Phase 1/2) testing.
Trial Status
Rejuva (RJVA-001) received Clinical Trial Authorization in the Netherlands in May 2026 to begin a Phase 1/2 first-in-human study for type 2 diabetes. First dosing and preliminary data were expected in H2 2026. However, on October 22, 2026, Fractyl Health announced it was discontinuing internal development of the Rejuva gene therapy program as part of a restructuring to focus on its Revita device. The company is seeking strategic alternatives (e.g., out-licensing or sale) for the program.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts for Rejuva — internal development discontinued. The company may announce a strategic alternative (license/partner/sale) for the program, but this is uncertain and not scheduled.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
FRACTYL HEALTH, INC. 8-K GUTS ·Originating report